Trends in NICE technology appraisals of non-small cell lung cancer drugs over the last decade
Technology appraisals became more complex over time due to the emergence of targeted therapies and immunotherapies, leading to multiple different indications, subpopulations and comparators that needed to be included in appraisals. Partitioned Survival Analysis (PartSA) models became the cornerstone within NSCLC, with time horizons up to 30 years and over time methods for indirect treatment comparisons became more established. The majority of the appraisals resulted in a positive recommendation for reimbursement.
Authors
- Guiling Zhou (ORCID: https://orcid.org/0000-0003-1872-0084)
- Lotte Westerink (ORCID: https://orcid.org/0000-0001-9515-1044)
- Cornelis Boersma (ORCID: https://orcid.org/0000-0002-1190-2638)
- Maarten Jacobus Postma (ORCID: https://orcid.org/0000-0002-6306-3653)
- Arjan Jacobus Postma
- Job F. M. van Boven (ORCID: https://orcid.org/0000-0003-2368-2262)
- Sharon Wolters
Institutions
- AstraZeneca (United Kingdom) (GB)
- University Medical Center Groningen (NL)
- University of Groningen (NL)
- Hanze University of Applied Sciences (NL)
- Open University of the Netherlands (NL)
- Padjadjaran University (ID)
Publication Details
- Journal
- The European Journal of Health Economics
- Published
- 2024-08-30
- DOI
- https://doi.org/10.1007/s10198-024-01711-0
- Citations
- 2
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.84